Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to evaluate the Pharmacokinetics, Safety and Tolerability of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System (registered) in Normal Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease

Next Previous
Trial Profile

A Phase 1 Study to evaluate the Pharmacokinetics, Safety and Tolerability of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System (registered) in Normal Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Lung disorders; Lung injury
  • Focus Adverse reactions
  • Sponsors Avalyn Pharma

Most Recent Events

  • 20 May 2025 According to Avalyn Pharma Inc. Media release, data from this study presented at the American Thoracic Society (ATS) International Conference 2025 being held May 16-21, 2025, in San Francisco, CA.
  • 06 May 2025 According to Avalyn Pharma Inc. Media release, topline data from this study will be presented at the American Thoracic Society (ATS) 2025 International Conference being held May 16-21, 2025, at the Moscone Center in San Francisco, CA.
  • 30 Mar 2023 According to an Avalyn Pharma media release, the company plans to present more detailed findings from the study at a medical meeting later in 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top